Fate of the teratogenic and carcinogenic ochratoxin A in human perfused placenta

Toxicology Letters

Volumn 208, Issue 1, 2012, Pages 92-99

  Woo, Chit Shing Jackson ^a   Partanen, Heidi ^b   Myllynen, Päivi ^c   Vähäkangas, Kirsi ^b   El Nezami, Hani ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Fetus; Ochratoxin A; Placental perfusion

Indexed keywords

ALBUMIN; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; OCHRATOXIN;

ARTICLE; CARCINOGENICITY; DRUG BLOOD LEVEL; DRUG TRANSPORT; FEMALE; FETUS CIRCULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; PLACENTA; PLACENTA PERFUSION; PLACENTAL TRANSFER; PREGNANT WOMAN; PRIORITY JOURNAL; TERATOGENICITY; TOXICOKINETICS;

ALBUMINS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOGENS; CARRIER PROTEINS; CELL LINE; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OCHRATOXINS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PERFUSION; PLACENTA; PREGNANCY; TERATOGENS;

ANIMALIA;

EID: 80755184754     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.10.013     Document Type: Article

References (51)

1. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., Schellens J.H., Koomen G.J., Schinkel A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 2002, 1:417-425.
2. Annola K., Heikkinen A.T., Partanen H., Woodhouse H., Segerback D., Vahakangas K. Transplacental transfer of nitrosodimethylamine in perfused human placenta. Placenta 2009, 30:277-283.
3. Annola K., Karttunen V., Keski-Rahkonen P., Myllynen P., Segerback D., Heinonen S., Vahakangas K. Transplacental transfer of acrylamide and glycidamide are comparable to that of antipyrine in perfused human placenta. Toxicol. Lett. 2008, 182:50-56.
4. Appelgren L.E., Arora R.G. Distribution of 14C-labelled ochratoxin A in pregnant mice. Food Chem. Toxicol. 1983, 21:563-568.
5. Appelgren L.E., Arora R.G. Distribution studies of 14C-labelled aflatoxin B1 and ochratoxin A in pregnant mice. Vet. Res. Commun. 1983, 7:141-144.
6. Ballinger M.B., Phillips T.D., Kubena L.F. Assessment of the distribution and elimination of ochratoxin A in the pregnant rat. J. Food Saf. 1986, 8:11-24.
7. Benirschke K., Kaufmann P., Baergen R.N. Pathology of the Human Placenta 2006, Springer Science+Business Media, New York, USA. 5th ed.
8. Berger V., Gabriel A.F., Sergent T., Trouet A., Larondelle Y., Schneider Y.J. Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a multidrug resistance-associated protein (MRP2). Toxicol. Lett. 2003, 140-141:465-476.
9. Biasucci G., Calabrese G., Di Giuseppe R., Carrara G., Colombo F., Mandelli B., Maj M., Bertuzzi T., Pietri A., Rossi F. The presence of ochratoxin A in cord serum and in human milk and its correspondence with maternal dietary habits. Eur. J. Nutr. 2010, 50:211-218.
10. Brandes J.M., Tavoloni N., Potter B.J., Sarkozi L., Shepard M.D., Berk P.D. A new recycling technique for human placental cotyledon perfusion: application to studies of the fetomaternal transfer of glucose, inulin, and antipyrine. Am. J. Obstet. Gynecol. 1983, 146:800-806.
11. Cha S.H., Sekine T., Kusuhara H., Yu E., Kim J.Y., Kim D.K., Sugiyama Y., Kanai Y., Endou H. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. 2000, 275:4507-4512.
12. Chu F.S. A comparative study of the interaction of ochratoxins with bovine serum albumin. Biochem. Pharmacol. 1974, 23:1105-1113.
13. Chu F.S. Interaction of ochratoxin A with bovine serum albumin. Arch. Biochem. Biophys. 1971, 147:359-366.
14. Chu F.S. Studies on ochratoxins. CRC Crit. Rev. Toxicol. 1974, 2:499-524.
15. EFSA Opinion of the scientific panel on contaminants in the food chain [CONTAM] related to ochratoxin A (OTA) as undesirable substance in animal feed. EFSA J. 2004, 101:1-36.
16. Faber J.J. Review of flow limited transfer in the placenta. Int. J. Obstet. Anesth. 1995, 4:230-237.
17. Fukui Y., Hoshino K., Kameyama Y., Yasui T., Toda C., Nagano H. Placental transfer of ochratoxin A and its cytotoxic effect on the mouse embryonic brain. Food Chem. Toxicol. 1987, 25:17-24.
18. Gekle M., Sauvant C., Schwerdt G. Ochratoxin A at nanomolar concentrations: a signal modulator in renal cells. Mol. Nutr. Food Res. 2005, 49:118-130.
19. Hagelberg S., Hult K., Fuchs R. Toxicokinetics of ochratoxin A in several species and its plasma-binding properties. J. Appl. Toxicol. 1989, 9:91-96.
20. Hallen I.P., Breitholtz-Emanuelsson A., Hult K., Olsen M., Oskarsson A. Placental and lactational transfer of ochratoxin A in rats. Nat. Toxins 1998, 6:43-49.
21. Hill M.D., Abramson F.P. The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin. Pharmacokinet. 1988, 14:156-170.
22. Jonsyn F.E., Maxwell S.M., Hendrickse R.G. Human fetal exposure to ochratoxin A and aflatoxins. Ann. Trop. Paediatr. 1995, 15:3-9.
23. Karttunen V., Myllynen P., Prochazka G., Pelkonen O., Segerback D., Vahakangas K. Placental transfer and DNA binding of benzo(a)pyrene in human placental perfusion. Toxicol. Lett. 2010, 197:75-81.
24. Leiser R., Kaufmann P. Placental structure: in a comparative aspect. Exp. Clin. Endocrinol. 1994, 102:122-134.
25. Loebstein R., Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther. Drug Monit. 2002, 24:15-22.
26. Marin-Kuan M., Cavin C., Delatour T., Schilter B. Ochratoxin A carcinogenicity involves a complex network of epigenetic mechanisms. Toxicon 2008, 52:195-202.
27. Mathiesen L., Mose T., Morck T.J., Nielsen J.K., Nielsen L.K., Maroun L.L., Dziegiel M.H., Larsen L.G., Knudsen L.E. Quality assessment of a placental perfusion protocol. Reprod. Toxicol. 2010, 30:138-146.
28. Mathiesen L., Rytting E., Mose T., Knudsen L.E. Transport of benzo[alpha]pyrene in the dually perfused human placenta perfusion model: effect of albumin in the perfusion medium. Basic Clin. Pharmacol. Toxicol. 2009, 105:181-187.
29. Miraglia, M., Brera, C., 2002. Task 3.2.7 assessment of dietary intake of ochratoxin A by the population of EU member states. Reports on tasks for scientific cooperation. Rome, Italy.
30. Myllynen P., Kummu M., Kangas T., Ilves M., Immonen E., Rysa J., Pirila R., Lastumaki A., Vähäkangas K.H. ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta. Toxicol. Appl. Pharmacol. 2008, 232:210-217.
31. Myllynen P.K., Pienimaki P.K., Vahakangas K.H. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur. J. Clin. Pharmacol. 2003, 58:677-682.
32. Nanovskaya T.N., Nekhayeva I., Hankins G.D., Ahmed M.S. Effect of human serum albumin on transplacental transfer of glyburide. Biochem. Pharmacol. 2006, 72:632-639.
33. Nielsen J.K.S., Vikström A.C., Turner P., Knudsen L.E. Deoxynivalenol transport across the human placental barrier. Food Chem. Toxicol. 2011, 49:2046-2052.
34. Pacifici G.M., Nottoli R. Placental transfer of drugs administered to the mother. Clin. Pharmacokinet. 1995, 28:235-269.
35. Partanen H.A., El-Nezami H.S., Leppanen J.M., Myllynen P.K., Woodhouse H.J., Vähäkangas K.H. Aflatoxin B1 transfer and metabolism in human placenta. Toxicol. Sci. 2010, 113:216-225.
36. Petzinger E., Ziegler K. Ochratoxin A from a toxicological perspective. J. Vet. Pharmacol. Ther. 2000, 23:91-98.
37. Pfohl-Leszkowicz A., Manderville R.A. Ochratoxin A: an overview on toxicity and carcinogenicity in animals and humans. Mol. Nutr. Food Res. 2007, 51:61-99.
38. Pienimaki P., Hartikainen A.L., Arvela P., Partanen T., Herva R., Pelkonen O., Vahakangas K. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 1995, 36:241-248.
39. Postupolski J., Karlowski K., Kubik P. Ochratoxin A in maternal and foetal blood and in maternal milk. Rocz. Panstw. Zakl. Hig. 2006, 57:23-30.
40. Ringot D., Chango A., Schneider Y.J., Larondelle Y. Toxicokinetics and toxicodynamics of ochratoxin A, an update. Chem. Biol. Interact. 2006, 159:18-46.
41. Rosner H., Rohrmann B., Peiker G. Ochratoxin A in human serum. Arch. Lebensmittelhyg. 2000, 51:104-107.
42. Schaut A., De Saeger S., Sergent T., Schneider Y.J., Larondelle Y., Pussemier L., Blank R., Van Peteghem C. Liquid chromatographic methods for biotransformation studies of ochratoxin A. Biomed. Chromatogr. 2008, 22:1013-1020.
43. Schneider H., Panigel M., Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol. 1972, 114:822-828.
44. Schrickx J., Lektarau Y., Fink-Gremmels J. Ochratoxin A secretion by ATP-dependent membrane transporters in Caco-2 cells. Arch. Toxicol. 2006, 80:243-249.
45. Smeets P.H., van Aubel R.A., Wouterse A.C., van den Heuvel J.J., Russel F.G. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol.: JASN 2004, 15:2828-2835.
46. Studer-Rohr I., Schlatter J., Dietrich D.R. Kinetic parameters and intraindividual fluctuations of ochratoxin A plasma levels in humans. Arch. Toxicol. 2000, 74:499-510.
47. Turner N.W., Subrahmanyam S., Piletsky S.A. Analytical methods for determination of mycotoxins: a review. Anal. Chim. Acta 2009, 632:168-180.
48. Valenta H. Chromatographic methods for the determination of ochratoxin A in animal and human tissues and fluids. J. Chromatogr. A 1998, 815:75-92.
49. Vähäkangas K., Myllynen P. Drug transporters in the human blood-placental barrier. Br. J. Pharmacol. 2009, 3:665-678.
50. Vähäkangas K., Myllynen P. Experimental methods to study human transplacental exposure to genotoxic agents. Mutat. Res. 2006, 608:129-135.
51. Zimmerli B., Dick R. Determination of ochratoxin A at the ppt level in human blood, serum, milk and some foodstuffs by high-performance liquid chromatography with enhanced fluorescence detection and immunoaffinity column cleanup: methodology and Swiss data. J. Chromatogr. B: Biomed. Appl. 1995, 666:85-99.